• Fitness and recovery
• Science & evidence
• Safety and quality
• FDA

PEG-MGF, the peptide named after your workout: what the muscle research found, and why FDA says it has no human data

By Peptide Policy Watch staff · Published November 10, 2026 · 9 min read · 20 sources, 20 checked at the source

Load a muscle hard, with heavy sets or a long downhill run, and something changes inside the fibers within hours. One stretch of the IGF-1 gene gets read a slightly different way, and in the late 1990s a London lab gave that version a catchy name: mechano growth factor, or MGF. Two decades later, a long-lasting "PEG" version of a small MGF fragment is sold online as a "research compound," according to a 2026 medical review, and it's on FDA's compounding agenda. [V] The biology behind the name is real. The question is how much of it carries over to the bottle.

Facts are as of November 10, 2026. Sources, with retrieval dates, are at the bottom.

Where the name comes from

Start with IGF-1, the growth factor your liver and muscles make, partly in response to growth hormone. The IGF-1 gene can be spliced into more than one version, the way a sentence can be cut and pasted into slightly different endings. In 1999, Geoffrey Goldspink's team in London reported that in rabbit leg muscle, stretch plus electrical stimulation sharply raised two IGF-1 versions within four days. They argued that one of them works locally, inside the muscle that made it, and named it mechano growth factor. [V] (Animal study.)

Human muscle shows the same kind of response. In a 2003 Journal of Physiology study, eight younger adults and seven adults in their 70s and early 80s did a heavy single-leg knee-extension session, and researchers took thigh-muscle biopsies about two and a half hours later. MGF messages rose significantly in the younger group but not in the older one, while the main IGF-1 version didn't change in either. [V] A follow-up with an hour of eccentric cycling, which is pedaling against a backward-turning crank, found MGF messages rising in both younger and older people. [V] (Small human biopsy studies; they measured the gene message, not a protein given to anyone.)

That's the strongest part of this story, and it's genuinely interesting: muscle seems to read the same gene differently depending on how it's been loaded, and age may blunt part of that response.

From a gene message to a lab-made peptide

Here's the leap that matters. What the biopsy studies measured is messenger RNA. The "MGF" sold as a peptide is something else: a synthetic copy of the final 24 amino acids of that IGF-1 version, called the E peptide. [V] A 2010 review in Endocrinology, led by a scientist at a U.S. Army research institute, made a pointed observation. At that time, nobody had isolated a matching peptide fragment from cells, tissues or body fluids. [V] So the synthetic peptide may be a useful lab tool without being a copy of something the body itself releases. [U] That's our reading of the review's point.

Naming adds to the confusion. In humans the variant is called IGF-1Ec; in rodents the matching one is IGF-1Eb. [V]

The lab results, for and against

The early wave. For about a decade, results from Goldspink's group and its collaborators kept pointing the same way: more muscle-cell growth in a dish, protection of brain and heart tissue in animals. [V] (Cell and animal studies, the usual first step for any medicine.)

The replication attempt. Then scientists at two drug companies, led by a Novartis team, tried to repeat the muscle-cell findings because MGF looked like a promising route to better muscle repair. They couldn't. The peptide didn't make mouse or human muscle cells grow, didn't hold back their maturation, and didn't change muscle stem cells, even though the same cells responded strongly to mature IGF-1 and to the full-length IGF-1 variant. The authors wrote that their results question whether MGF has a physiological role at all. [V] (Cell study.)

That's a real scientific disagreement, not a settled verdict either way. Different labs, different peptide batches and different cell setups can give different answers. [U] What it does mean is that the case for MGF rests on lab and animal work that hasn't been cleanly reproduced, and on no published treatment trials in people that we could find.

• 24amino acids in the lab-made MGF peptide [V]
• 0registered human trials of MGF or PEG-MGF we found on ClinicalTrials.gov [V]
• 5substances on FDA's next compounding advisory agenda, PEG-MGF among them [V]

What the "PEG" adds

PEGylation means bolting chains of polyethylene glycol onto a protein so the body clears it more slowly. It's a well-established drug-engineering move. FDA approved Amgen's pegfilgrastim (Neulasta), a pegylated protein drug, in January 2002. [V] It's been tried on IGF-1 itself too: in a 2017 Roche first-in-human study of 62 healthy volunteers, a pegylated full-length IGF-1 had a half-life of roughly six to eight days, and it was well tolerated. [V] (Small randomized early-phase trial of a different molecule.)

None of that tells us how a pegylated MGF fragment behaves in a person, because nobody has published that study. [U]

Where it stands with FDA and in sport

Approval. No FDA-approved drug contains MGF or PEG-MGF; an openFDA Drugs@FDA search for mechano growth factor returned no match. [V] The only FDA-approved IGF-1 medicine is mecasermin (Increlex), approved in 2005 for children with severe primary IGF-1 deficiency, a rare growth disorder. [V]

Compounding. FDA's safety-risks page lists mechano growth factor pegylated in the table of substances once in category 2 whose nominations were later withdrawn. FDA's entry, summarized: possible significant immune reactions for some routes, difficulty characterizing the peptide and its impurities, no human exposure data for any route, and too little safety information to know whether it would harm people. [V] Plain, non-pegylated MGF sits in category 3 of FDA's 503ASection of federal drug law covering compounding by state-licensed pharmacies and doctors, usually for a prescription written for one patient. Glossary entry nominations list, updated May 14, 2026, meaning it was nominated without enough supporting information to evaluate. [V] Our compounding categories explainer explains each category.

The advisory meeting. FDA's Pharmacy Compounding Advisory Committee page lists PEG-MGF with LL-37, GHK-Cu, dihexa acetate and melanotan II for discussion as possible additions to the 503A bulks list. No date has been posted. [V] Our meeting preview covers all five, and our LL-37 and melanotan II pages cover two of them. PEG-MGF isn't one of the six peptides in HHS's October 2026 compounding policy. [V]

Sport. WADA's 2026 Prohibited List names mechano growth factors in section S2.3, growth factors, which is banned in and out of competition. [V] Anti-doping chemists led by Mario Thevis wrote in 2014 that MGF has been prohibited since 2005, described a full-length version being offered to athletes through illicit channels, and built a test that detects it. [V] Our WADA list guide covers the other gym peptides on it.

Limits and unknowns

• No human treatment data. FDA says it found no human exposure data for PEG-MGF, and we found no registered trial or published treatment study in people. [V]
• A replication problem. The best-known muscle-cell findings didn't hold up in a careful independent test in 2014. [V]
• Growth signals cut both ways. A 2026 review of performance peptides in Frontiers in Endocrinology grouped PEG-MGF with other IGF-1 analogues and called concerns about unwanted cell growth biologically plausible but unproven. [V]
• What's in the vial. Products sold outside pharmacies get no FDA quality check. Our label decoder explains what "research use only" does and doesn't mean. [U]

What to watch

The clearest next step is FDA's advisory meeting. When the agency posts briefing documents, they'll show its full review of PEG-MGF, which today it only summarizes in a few lines. Until then, MGF sits in a strange spot: a real, measurable response in exercising muscle, a lab peptide built from one piece of it, and a research record that split in two before it ever reached people. For how a lab finding turns into evidence, see our evidence ladder and why most drugs in trials never get approved. The 14-peptide status table has the bigger picture.

Sources (retrieved November 10, 2026)

1. FDA, "Certain bulk drug substances for use in compounding that may present significant safety risks," content current as of April 22, 2026 [V] — https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
2. FDA, "Meeting of the Pharmacy Compounding Advisory Committee," content current as of April 15, 2026 [V] — https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee
3. FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (Categories 1-3), updated May 14, 2026 [V] — https://www.fda.gov/media/94155/download
4. openFDA Drugs@FDA search for mechano growth factor, no matching application (checked November 10, 2026) [V] — https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:mechano
5. McKoy G et al., "Expression of insulin growth factor-1 splice variants and structural genes in rabbit skeletal muscle induced by stretch and stimulation," J Physiol 1999;516(Pt 2):583-92, PMID 10087355 [V] — https://pubmed.ncbi.nlm.nih.gov/10087355/
6. Hameed M et al., "Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise," J Physiol 2003;547(Pt 1):247-54, PMID 12562960 [V] — https://pubmed.ncbi.nlm.nih.gov/12562960/
7. Hameed M et al., "Effects of eccentric cycling exercise on IGF-I splice variant expression in the muscles of young and elderly people," Scand J Med Sci Sports 2008;18(4):447-52, PMID 18067523 [V] — https://pubmed.ncbi.nlm.nih.gov/18067523/
8. Matheny RW Jr, Nindl BC, Adamo ML, "Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration," Endocrinology 2010;151(3):865-75, PMID 20130113 [V] — https://pubmed.ncbi.nlm.nih.gov/20130113/
9. Yang SY, Goldspink G, "Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation," FEBS Lett 2002;522(1-3):156-60, PMID 12095637 [V] — https://pubmed.ncbi.nlm.nih.gov/12095637/
10. Dluzniewska J et al., "A strong neuroprotective effect of the autonomous C-terminal peptide of IGF-1 Ec (MGF) in brain ischemia," FASEB J 2005;19(13):1896-8, PMID 16144956 [V] — https://pubmed.ncbi.nlm.nih.gov/16144956/
11. Carpenter V et al., "Mechano-growth factor reduces loss of cardiac function in acute myocardial infarction," Heart Lung Circ 2008;17(1):33-9, PMID 17581790 [V] — https://pubmed.ncbi.nlm.nih.gov/17581790/
12. Kandalla PK et al., "Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages," Mech Ageing Dev 2011;132(4):154-62, PMID 21354439 [V] — https://pubmed.ncbi.nlm.nih.gov/21354439/
13. Fornaro M et al., "Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells," Am J Physiol Endocrinol Metab 2014;306(2):E150-6, PMID 24253050 [V] — https://pubmed.ncbi.nlm.nih.gov/24253050/
14. Kletzl H et al., "First-in-man study with a novel PEGylated recombinant human insulin-like growth factor-I," Growth Horm IGF Res 2017;33:9-16, PMID 28110155 [V] — https://pubmed.ncbi.nlm.nih.gov/28110155/
15. openFDA Drugs@FDA, BLA 125031, Neulasta (pegfilgrastim), Amgen, original approval January 31, 2002 [V] — https://api.fda.gov/drug/drugsfda.json?search=openfda.brand_name:neulasta
16. openFDA drug label, Increlex (mecasermin) indications, label effective August 5, 2025; Drugs@FDA application 021839, original approval August 30, 2005 [V] — https://api.fda.gov/drug/label.json?search=openfda.brand_name:increlex
17. WADA, 2026 Prohibited List (S2.3, growth factors), published September 2025 [V] — https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
18. Thevis M et al., "Mass spectrometric characterization of a biotechnologically produced full-length mechano growth factor (MGF) relevant for doping controls," Growth Horm IGF Res 2014;24(6):276-80, PMID 25466910 [V] — https://pubmed.ncbi.nlm.nih.gov/25466910/
19. Dominikowski A et al., "The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis," Front Endocrinol 2026;17:1822475, PMID 42395176 [V] — https://pubmed.ncbi.nlm.nih.gov/42395176/
20. ClinicalTrials.gov searches for "mechano growth factor," "PEG-MGF" and "IGF-1Ec" (no interventional trial of MGF or PEG-MGF found; checked November 10, 2026) [V] — https://clinicaltrials.gov/search?term=mechano%20growth%20factor

Spot a mistake? See how we source and our corrections policy.

Image: AI-generated. Image credits